30 results about "Molecular phenotype" patented technology

A system and method for analyzing a data store of de-identified patient data to generate one or more dynamic user interfaces usable to predict an expected response of a particular patient population or cohort when provided with a certain treatment. The automated analysis of patterns occurring in patient clinical, molecular, phenotypic, and response data, as facilitated by the various user interfaces, provides an efficient, intuitive way for clinicians to evaluate large data sets to aid in the potential discovery of insights of therapeutic significance.

Disclosed are platforms, systems, media, and methods for enabling a clinical trial administrator to identify individuals potentially eligible for a clinical trial based at least in part on an individual molecular phenotype, review profiles of identified individuals, and make clinical trial enrollment offers to identified individuals. Also disclosed are platforms, systems, media, and methods for enabling a patient to review and accept or decline clinical trial enrollment offers and identify relevant individuals, clinical trials, and therapies based at least in part on an individual molecular phenotype.

The invention relates to the technical field of biomedical engineering and particularly relates to a long-term in-vitro culture and directional differentiation system and method for a liver stem cell. The long-term in-vitro culture and directional differentiation system comprises an amplification culture medium with specific chemical components, and a differential medium with specific chemical components, wherein the amplification culture medium is used for carrying out in-vitro culture of a mouse or human liver stem cell, and the differential medium is used for carrying out induced differentiation on the mouse or human liver stem cell to form a matured liver cell. By using the long-term in-vitro culture and directional differentiation system and method, a selectively-amplified liver stem cell in mother cells of the liver can be obtained from a mouse embryonic liver tissue or through human multipotential stem cell differentiation, the liver stem cell can be cultured for more than 20 generations under such a condition, and the stable molecular phenotype of the liver stem cell is maintained. By using the long-term in-vitro culture and directional differentiation system and method, the cultured mouse or human liver stem cell can be further subjected to induced differentiation to form the matured liver cell with functions of secreting albumin, metabolizing urea and the like.

The invention discloses an imaging device and a method for quickly acquiring 3D structure information and molecular phenotype information of a large sample. The device comprises a sample storage device, a 3D mobile station used for driving the sample storage device to move in a 3D space, a vibration slicing module used for slicing a sample to get the shallow part of the sample, and a wide-field optical microscopic imaging module used for performing high-throughput tomography imaging on the shallow part of the sample. The defects in the prior art, for example, the sample preparation process is complex, the sample shape and fluorescence signals are affected, and imaging is slow, are solved. The 3D structure information of a sample can be quickly acquired and analyzed, and the acquired data has the characteristic of auto-registration. Moreover, molecular phenotype dyeing is performed on a sample slice of a part of interest to get the molecular phenotype information of the sample, and the molecular phenotype information can be registered into the acquired 3D structure information.

The invention relates to the technical field of biomedical engineering, particularly to a directional differentiation system and method for liver stem cells for long term invitro culture of liver stem cells. The directional differentiation system comprises an expansion culture medium with explicit chemical compositions, which is used for invitro culture of mouse or human liver stem cells, and a differentiation culture medium with explicit chemical compositions, which is used for changing the mouse or human liver stem cells to be mature liver cells through induced differentiation. According to the system and method provided by the invention, liver stem cells from mouse fetal liver tissue or hepatic progenitor cells obtained through human pluripotent stem cell differentiation are selectively expanded, the liver stem cells are cultivated for more than 20 generations under the condition, and stable liver stem cell molecular phenotype can be maintained; further, the cultured mouse or human liver stem cells are changed through induced differentiation of the mouse or human liver stem cells to be mature liver cells with functions of secreting albumin, metabolizing urea and the like.

The described invention provides a system and method for clinical outcome tracking and analysis. The clinical outcome tracking and analysis comprises sorting, outcome tracking, quality of life metrics, toxicity to therapy and cost of care. The system and method includes receiving one or more parameters. Exemplary parameters for sorting include sex, age, ethnicity, comorbidities, tobacco use, source of insurance, medical record number, primary care physician, referring physician, hospital, approved service vendors, disease-specific clinical molecular phenotype, therapy intent, stage of therapy, biomarkers, and cost of care.

Methods and compositions to impute or predict genotype, haplotype, molecular phenotype, agronomic phenotypes, and / or coancestry are provided. Methods and compositions provided include using latent space to generate latent space representations or latent vectors that are independent of underlying genotypic or phenotypic data. The methods may include generating a universal latent space representation by encoding discrete or continuous variables derived from genotypic or phenotypic data into latent vectors through a machine learning-based encoder framework. Provided herein are universal methods of parametrically representing genotypic or phenotypic data obtained from one or more populations or sample sets to impute or predict a genotype or phenotype of interest.

The invention discloses an EpCAM / PSMA dual-antibody-based functionalized micro-fluidic chip as well as a preparation method and application thereof. The invention also discloses a method for capturingprostatic cancer CTCs by using the EpCAM / PSMA dual-antibody-based functionalized micro-fluidic chip as well as method for analyzing relevant molecular characteristic spectrum for the captured prostatic cancer CTCs. The relevant molecular phenotype is a prostatic cancer transfer relevant marker SChLAP1 / PSA as well as targeting treatment response marker AR / PD-L1, so that a prostatic cancer CTCs molecular characteristic spectrum joint detection method and a detection kit can be constructed. The EpCAM / PSMA dual-antibody-based functionalized micro-fluidic chip is effective, high in specificity, high in sensitivity and high in accuracy, and also has clinical practical value, and the tetramolecular joint detection is used for the early warning of the transfer and reoccurrence and the curative effect evaluation in the prostatic cancer CTCs as well as improves the feasibility and credibility of the clinical use by virtue of the targeting treatment.

A system and method for analyzing a data store of de-identified patient data to generate one or more dynamic user interfaces usable to predict an expected response of a particular patient population or cohort when provided with a certain treatment. The automated analysis of patterns occurring in patient clinical, molecular, phenotypic, and response data, as facilitated by the various user interfaces, provides an efficient, intuitive way for clinicians to evaluate large data sets to aid in the potential discovery of insights of therapeutic significance.

A system and method for analyzing a data store of de-identified patient data to generate one or more dynamic user interfaces usable to predict an expected response of a particular patient population or cohort when provided with a certain treatment. The automated analysis of patterns occurring in patient clinical, molecular, phenotypic, and response data, as facilitated by the various user interfaces, provides an efficient, intuitive way for clinicians to evaluate large data sets to aid in the potential discovery of insights of therapeutic significance.

Methods and compositions to impute or predict genotype, haplotype, molecular phenotype, agronomic phenotypes, and / or coancestry are provided. Methods and compositions provided include using latent space to generate latent space representations or latent vectors that are independent of underlying genotypic or phenotypic data. The methods may include generating a universal latent space representation by encoding discrete or continuous variables derived from genotypic or phenotypic data into latent vectors through a machine learning-based encoder framework. Provided herein are universal methods of parametrically representing genotypic or phenotypic data obtained from one or more populations or sample sets to impute or predict a genotype or phenotype of interest.

The invention provides a separation method for hepatic inherent and infiltrating macrophages. The separation method comprises the following steps of (1) establishing and identifying mouse allogeneicbone marrow transplantation model, wherein a surface marker of a mononuclear macrophage of a recipient mouse is CD45.2, and a surface marker of a mononuclear macrophage of a donor mouse is CD45.1; (2)observing and irradiating the influence on hepatic parenchymal cells and inherent macrophages with an IHC method and a flow cytometry; and (3) irradiating a mononuclear cell of a mouse liver in a transplantation group with primary isolation, and sorting the hepatic inherent and infiltrating macrophages with the flow cytometry according to the surface marker of the mononuclear macrophage of the donor mouse, and describing the quantities, distribution and phenotypes of the hepatic inherent and infiltrating macrophages. In the separation method provided by the invention, by removing the CD45.2 recipient mouse bone marrow derived macrophages by irradiation and supplementing and replacing bone marrow cells of the recipient mouse with CD45.1 donor mouse bone marrows, the bone marrow derived infiltrating macrophages and the bone marrow derived inherent macrophages have different molecular phenotypes and achieves the effect of accurately and efficiently separating different hepatic macrophages.

Aspects of the present disclosure include methods of producing modified polypeptides and modified polypeptide-ribosome or polypeptide-mRNA complexes, and methods of screening polynucleotide and polypeptide libraries. The present disclosure also provides polypeptide libraries useful in screening for single molecule phenotypes. Also provided are kits useful for producing polypeptides capable of being modified using methods disclosed herein.

A system and method for analyzing a data store of de-identified patient data to generate one or more dynamic user interfaces usable to predict an expected response of a particular patient population or cohort when provided with a certain treatment. The automated analysis of patterns occurring in patient clinical, molecular, phenotypic, and response data, as facilitated by the various user interfaces, provides an efficient, intuitive way for clinicians to evaluate large data sets to aid in the potential discovery of insights of therapeutic significance.

Heritable mutations in the BRCA1 and BRCA2 and other genes in the DNA double-strand break (DSB) repair pathway increase risk of breast, ovarian and other cancers. In response to DNA breaks, the proteins encoded by these genes bind to each other and are transported into the nucleus to form nuclear foci and initiate homologous recombination. Flow cytometry-based functional variant analyses (FVAs) were developed to determine whether variants in BRCA1 or other DSB repair genes disrupted the binding of BRCA1 to its protein partners, the phosphorylation of p53 or the transport of the BRCA1complex to the nucleus in response to DNA damage. Each of these assays distinguished high-risk BRCA1 mutations from low-risk BRCA1 controls. Mutations in other DSB repair pathway genes produced molecular phenocopies with these assays. FVA assays may represent an adjunct to sequencing for categorizing VUS or may represent a stand-alone measure for assessing breast cancer risk.

Chronic inflammation is an increasing medical problem area of high socioeconomic significance. The invention relates to a method and a kit for diagnosing a molecular phenotype of a patient suffering from an illness accompanied by chronic inflammation, and to a medicament for treating such a patient. To that end, the gene expression of GATA-3 and / or Tbet in a biological isolate of the patient is measured and used for association with a molecular phenotype of the illness.

A system and method for analyzing a data store of de-identified patient data to generate one or more dynamic user interfaces usable to predict an expected response of a particular patient population or cohort when provided with a certain treatment. The automated analysis of patterns occurring in patient clinical, molecular, phenotypic, and response data, as facilitated by the various user interfaces, provides an efficient, intuitive way for clinicians to evaluate large data sets to aid in the potential discovery of insights of therapeutic significance.

The invention discloses a kiwi berry natural heterozygote identification method, and relates to the fields of plant genetic resource evaluation and the biotechnology. The method concretely includes the following steps: 1, collecting natural heterozygous samples to be identified and hypothetical control parents; 2, carrying out genome heredity analysis on the sample by using a microsatellite molecule marker; 3, constructing the microsatellite molecule phenotype database of all the samples; 4, determining a true control parent by using multiple correspondence analysis of the molecular phenotype data; and 5, identifying the natural heterozygote based on the control parent. Compared with traditional kiwi berry natural heterozygote identification methods, the kiwi berry natural heterozygote identification method has the characteristics of simple molecular experimental process, fast and efficient analysis and identification flow, and the like; the method can overcome the problems of difficult kiwi berry pure and control sample determination, difficult processing of complex data of genome ploidy, and the like; and the method also can mitigate the influences of genetic coancestry on the heterozygote identification.

The invention discloses an EpCAM / PSMA dual-antibody-based functionalized micro-fluidic chip as well as a preparation method and application thereof. The invention also discloses a method for capturingprostatic cancer CTCs by using the EpCAM / PSMA dual-antibody-based functionalized micro-fluidic chip as well as method for analyzing relevant molecular characteristic spectrum for the captured prostatic cancer CTCs. The relevant molecular phenotype is a prostatic cancer transfer relevant marker SChLAP1 / PSA as well as targeting treatment response marker AR / PD-L1, so that a prostatic cancer CTCs molecular characteristic spectrum joint detection method and a detection kit can be constructed. The EpCAM / PSMA dual-antibody-based functionalized micro-fluidic chip is effective, high in specificity, high in sensitivity and high in accuracy, and also has clinical practical value, and the tetramolecular joint detection is used for the early warning of the transfer and reoccurrence and the curative effect evaluation in the prostatic cancer CTCs as well as improves the feasibility and credibility of the clinical use by virtue of the targeting treatment.

A system and method for analyzing a data store of patient data to generate one or more dynamic user interfaces usable to predict an expected response of a particular patient population or cohort when provided with a certain treatment. The automated analysis of patterns occurring in patient clinical, molecular, phenotypic, and response data, as facilitated by the various user interfaces, provides an efficient, intuitive way for clinicians to evaluate large data sets to aid in the potential discovery of insights of therapeutic significance.

The present invention relates to a method for single-cell imaging mass spectrometry (MS) by correlating an optical image of a cell sample with an MS image. The method of the invention is in particular useful in research to test concomitantly optical and molecular phenotypes at a single-cell resolution.

The invention relates to the technical field of biomedical engineering, and provides a human gallbladder stem cell acquisition and long-term in-vitro culture method. The method comprises a human gallbladder stem cell acquisition method and a human gallbladder stem cell long-term in-vitro culture method. A primary culture medium and a cell expansion culture medium with clear chemical components areprovided. By adopting the two culture media, selective amplification of the gallbladder stem cells in human gallbladder tissues is realized, the cells can be continuously cultured in vitro for more than 100 days under the condition, and a stable liver stem cell related molecular phenotype is maintained; after induced differentiation, the cells have partial liver functions, including ingestion oflow-density lipoprotein, synthesis of fat and storage of glycogen. Therefore, the gallbladder stem cells obtained by the method can be used as seed cells for cell therapy of liver failure diseases, and can be used for drug screening and preparation of tissue engineering liver and artificial liver.

A method for identifying CD44 and CD24 molecular phenotypes comprises a first antibody-nucleic acid conjugate specifically binding to CD44 protein on the surface of a cell, a second antibody-nucleic acid conjugate specifically binding to CD24 protein on the surface of the cell, a DNA single-stranded T chain and a DNA single-stranded F chain, wherein the T chain is complementarily bound to the nucleic acid chain of the first antibody-nucleic acid conjugate. The F chain and the nucleic acid chain of the second antibody-nucleic acid conjugate are complementarily combined to form a programmed DNA loop together, the signal marker on the surface of the CD44 positive CD24 positive phenotypic cell is erased, and the signal probe marked to the cell is retained. The method provided by the invention realizes recognition and effective distinguishing of CD44 and CD24 molecular phenotype cells, and has the characteristics of simple operation, accurate result, low technical level requirement, small data analysis amount and the like.

The invention provides an in-vitro induction and long-term culture system, an induced culture method and application of forebrain neural stem cells. The in-vitro induction and long-term culture system comprises a basal culture medium, as well as an induced differentiation factor and an in-vitro culture factor which are combined with the basal culture medium for use, wherein the basal culture medium comprises a DMEM / F12 liquid basal culture medium, a 0-5*B27 additive, a 0-5*N2 additive, 1% penicillin / streptomycin and 0.01-500 mu g / mL 2-phosphoric acid- vitamin C; the induced differentiation factor comprises 0.01-500 mu M of a TGF[beta] inhibitor, 0.01-10000 mu M of a BMP inhibitor and 0.01-50 mu M of a Porcupine inhibitor; and the in-vitro culture factor comprises 0.01-10000 nM of an Src kinase inhibitor, 0.01-500 mu M of a TGF[beta] inhibitor, 0.01-50 mu M of a GSK3 inhibitor, 0.01-500 ng / mL of an EGF family growth factor and 0.01-500 ng / mL of an FGF family growth factor. By using the culture system, the pluripotent stem cells can be induced in vitro to be differentiated into the forebrain neural stem cells and cultured in vitro for a long time, and the stable molecular phenotype and differentiation potential of the forebrain neural stem cells are maintained.

Heritable pathogenic variants in the mismatch repair (MMR) pathway, also known as Lynch Syndrome (LS), can lead to the development of colon cancer and other cancers. Following mismatch, a complex of proteins consisting of MLH1, MSH2, MSH6 and PMS2 translocate into the nucleus to signal recruitment of repair mechanisms. Flow cytometry-based, functional variant assays (FVAs), were developed to determine whether variants in these MMR repair genes and / or other related genes would augment the nuclear translocation of MLH1 and MSH2 and downstream nuclear phosphorylation of ATM and ATR in response to DNA mismatches. Each assay distinguished pathogenic variants in MMR repair genes (MLH1, MSH2, PMS2 and MSH6) from benign controls. The combination of multiple assays provided robust separation between heterozygous pathogenic variant carriers and benign controls. The ability to produce distinct molecular phenotypes by these assays suggest FVA assays of MMR pathways could be used to identify LS and associated risk of colon and other cancers and could act as an adjunct to MMR gene sequencing panels in categorizing variants.

An imaging device and method for quickly acquiring large-sample three-dimensional structure information and molecular phenotype information. The apparatus comprises: a sample storage device; a three-dimensional mobile station (9) for driving the sample storage device to move within a three-dimensional space; a vibration slicing module (8) for slicing the sample (5) so that the sample obtains a superficial-layer portion; and a wide-field optical microimaging module for performing high-throughput tomography on the superficial-layer portion of the sample. By means of the device and method, the disadvantages in the prior art that a sample preparation flow is complex, a sample form and a fluorescence signal are affected and an imaging speed is slow are solved, and three-dimensional structure information about a sample can be quickly acquired and analyzed, wherein the acquired data has an auto-registration characteristic, molecular phenotype dyeing is performed on a sample slice in a position of interest to obtain molecular phenotype information about the sample, and same can be registered into the acquired three-dimensional structure information.

Heritable mutations in the BRCA1 and BRCA2 and other genes in the DNA double-strand break (DSB) repair pathway increase risk of breast, ovarian and other cancers. In response to DNA breaks, the proteins encoded by these genes bind to each other and are transported into the nucleus to form nuclear foci and initiate homologous recombination. Flow cytometry-based functional variant analyses (FVAs) were developed to determine whether variants in BRCA1 or other DSB repair genes disrupted the binding of BRCA1 to its protein partners, the phosphorylation of p53 or the transport of the BRCA1 complex to the nucleus in response to DNA damage. Each of these assays distinguished high-risk BRCA1 mutations from low-risk BRCA1 controls. Mutations in other DSB repair pathway genes produced molecular phenocopies with these assays. FVA assays may represent an adjunct to sequencing for categorizing VUS or may represent a stand-alone measure for assessing breast cancer risk.